Stryker Corporation (SYK)
Stryker: This Dividend Aristocrat Is Finally Cheap Again
Stryker is upgraded to 'Strong Buy' after a significant price pullback to $275, offering compelling value relative to historical valuation. SYK demonstrates robust organic sales growth, balanced across geographies and segments, with strong demand and elevated equipment backlogs. Key growth drivers include Mako robotic-assisted procedures, ASC expansion, and Smart Care platform integration, supporting double-digit EPS growth expectations.
Stryker Expands Foot & Ankle Innovation With Prophecy and smartHEX
SYK expands its Foot & Ankle portfolio with Prophecy for Incompass and smartHEX, linking planning, implants and limb reconstruction.
Stryker: Operational Issues Have Created An Opportunity
Stryker's share price has declined significantly in recent months on the back of operational issues, valuation concerns, and weaker orthopedic procedure volume growth. Despite headwinds, Stryker's growth is still solid and should rebound once the Vascular manufacturing issue is resolved. Further margin expansion is also an underappreciated part of the Stryker story.
Stryker Corporation (SYK) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Stryker Corporation (SYK) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Intuitive Surgical Vs. Stryker: Wall Street Loves Both But One Has a Quiet Advantage That Will Make Investors Money
Both Intuitive Surgical and Stryker just posted their fifth straight earnings beat, and Wall Street is cheering for both. But a structural difference buried inside their business models quietly separates a compounder from a cyclical recovery story.
Stryker Launches FDA-Cleared Apple Vision Pro Surgical App
SYK's FDA-cleared SportSuite Vision brings Apple Vision Pro into hip arthroscopy, strengthening its digital surgery push and Sports Medicine portfolio.
Stryker to Acquire ZuriMED to Expand Its Shoulder Care Portfolio
SYK's planned ZuriMED acquisition adds the FiberLocker System, aiming to strengthen its shoulder portfolio and rotator cuff care capabilities.
Do Options Traders Know Something About Stryker Stock We Don't?
Investors need to pay close attention to SYK stock based on the movements in the options market lately.
Here's Why You Should Hold Stryker Stock in Your Portfolio for Now
SYK's resilient demand, Mako robotics growth and margin gains support its outlook despite cyber and supply disruptions.
Stryker: The Sell-Off Creates A Better Entry Point, But Q2 Wasn't Perfect
Stryker (SYK) rebounded in Q2 with 9% organic growth, restoring confidence after a weak Q1. Both MedSurg & Neurotech and Orthopaedics segments sharply accelerated, indicating Q1 weakness was temporary. Guidance was modestly adjusted, but demand remains strong and growth is broad-based across product lines.
SYK Stock Gains 3.8% Since March-End: What's Driving the Uptrend?
Stryker has gained 3.8% since March-end as Mako robotics, hospital capital demand and international growth drive momentum.
Is SYK Worth Buying as Growth Improves but Execution Risks Persist?
Stryker's stronger growth, margin gains and product pipeline support the case, but cyber costs, supply constraints and acquisition execution keep risks elevated.
